4.5 Article

Migraine in the Triptan Era: Lessons From Epidemiology, Pathophysiology, and Clinical Science

Journal

HEADACHE
Volume 49, Issue -, Pages S21-S33

Publisher

WILEY
DOI: 10.1111/j.1526-4610.2008.01336.x

Keywords

triptans; migraine epidemiology; pathophysiology

Funding

  1. AGA
  2. Advanced NeuroModulation Systems
  3. Allergan, Boston Scientific
  4. Coherex
  5. Endo Pharmaceuticals
  6. GlaxoSmithKline
  7. Lilly
  8. MAP
  9. Medtronic
  10. Merck
  11. NuPath
  12. Valeant Pharmaceuticals
  13. Almirall
  14. CoLucid
  15. Eisai
  16. Linde
  17. Menarini
  18. NWO
  19. NIH
  20. European Community FPG
  21. Biomed EC
  22. Dutch Heart Foundation

Ask authors/readers for more resources

The triptan era has been a time of remarkable progress for migraine diagnosis and treatment. In this paper, we review some of the advances achieved in migraine science during this era focusing on 3 themes: lessons from clinical practice, lessons from epidemiology and lessons from pathophysiology. Science has shown that migraine is a disorder of the brain, and that the key events happen in the the trigeminal neuronal pathways, not on blood vessels. Clinical science has led to the observation that migraine sometimes progresses or remits. This in turn led to longitudinal epidemiologic studies focusing on factors that determine migraine prognosis. In addition, these studies raised questions about the mechanisms of migraine progression, including the role of allodynia, obesity, inflammation, and medications as determinants of progression. This in turn opens a new set of scientific questions about the neurobiologic determinants of migraine, as well as of its clinical course, and exciting opportunities to develop new therapies for this highly disabling brain disorder.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available